vimarsana.com

Page 90 - அமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Finerenone Cuts CV Events in CKD Patients With Diabetes: FIGARO-DKD

May 11, 2021 The addition of finerenone to standard medical therapy significantly reduces the risk of cardiovascular mortality and other cardiovascular events in patients with chronic kidney disease (CKD) and type 2 diabetes, according to topline results from FIGARO-DKD announced this week. Bayer, the maker of the investigational mineralocorticoid receptor antagonist (MRA), announced that the large-scale study met its primary endpoint reduction in the risk of first occurrence of CV mortality, MI, stroke, or heart failure hospitalization in the approximately 7,400 patients randomized in the trial. The positive study is the second trial showing a benefit of finerenone in patients with CKD and type 2 diabetes. In the FIDELIO-DKD trial, led by George Bakris, MD (University of Chicago, IL), finerenone reduced the risk of kidney failure or death from renal causes, the study’s primary endpoint, and reduced the risk of CV mortality, MI, stroke, or heart failure hospitalization. Unlike

Hostility Is Common in Cardiology: Can a New ACC/AHA Statement Help?

  The contemporary cardiology workplace is fraught with hostility, including discrimination and harassment, according to new data from a global survey. A very low response rate, however, raises questions as to why clinicians refrained from participating in the project. Also this week, the American College of Cardiology and American Heart Association (ACC/AHA), released a consensus report on professionalism and ethics that potentially could help rectify many of the issues hindering physician well-being in the workplace. The survey, published in the May 18, 2021, issue of the Journal of the American College of Cardiology, is far from the first to document a challenging culture in medicine generally and in cardiology specifically. But lead author Garima Sharma, MD (Johns Hopkins University School of Medicine, Baltimore, MD), told TCTMD it is the first to consolidate international perspectives: from Africa, Asia, the Caribbean, Eastern Europe, the European Union, the Middle East, O

Efficacy Of Repatha® Across High-Risk Patient Populations Reinforced At ACC 21

Amgen today announced the presentation of four cardiovascular research abstracts, including final data from the Repatha ® open label extension trial of patients living with HIV who have high cholesterol, as well as new data from FOURIER evaluating biomarkers of major cardiovascular events, including complex revascularization procedures. Additional abstracts to be presented include a simulation comparing the impact … Amgen (NASDAQ:AMGN) today announced the presentation of four cardiovascular research abstracts, including final data from the Repatha ® (evolocumab) open label extension trial of patients living with HIV who have high cholesterol, as well as new data from FOURIER evaluating biomarkers of major cardiovascular (CV) events, including complex revascularization procedures. Additional abstracts to be presented include a simulation comparing the impact of different LDL-C guidelines on CV risk reduction, as well as negative control outcomes to assess residual bias when compa

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.